D-Wave Quantum's Summer of Substance Collides With a Share Price in Retreat

D-Wave's stock falls 64% from peak despite Nature publication and NTT DOCOMO, Nasdaq Verafin deals; CFO departure adds pressure.

There is a peculiar disconnect playing out at D-Wave Quantum right now: the company's laboratory and partnership pipeline has rarely looked more productive, yet the stock keeps sliding. Investors who bought at last October's peak are sitting on a 64 percent loss, a brutal markdown for a firm that has spent the past month stacking up scientific validations and blue-chip collaborations.

The most recent piece of turbulence came last Wednesday, when the company disclosed that CFO John Markovich would step down on September 2. The announcement knocked 2.3 percent off the share price, extending a run of weakness that has left the stock down 35 percent since the start of the year. Greg Golkov, previously senior vice president of finance, steps in as interim chief financial officer and will also take on the principal accounting officer role on a transitional basis.

Yet framing the CFO departure as the headline story would miss the broader picture. D-Wave has been quietly assembling evidence that its technology is moving from theoretical promise toward commercial viability — even if the revenue figures don't yet reflect it.

A Research Breakthrough With Real Credentials

On August 5, the company unveiled a hardware milestone in gate-model quantum computing: a superconducting dual-rail qubit architecture featuring a high-precision two-qubit entangling gate. The work is tied to results published in Nature, a peer-reviewed validation that carries weight for a company long associated primarily with annealing technology. The advance signals a deliberate broadening of D-Wave's technological base beyond its traditional annealing focus.

The commercial side has been equally active. NTT DOCOMO brought a second production quantum application online on August 18, expanding an existing partnership that originally centered on network-area tracking. Nasdaq Verafin came aboard on August 3 for a joint effort to build a quantum application aimed at detecting financial crime. And on August 21, Canada's National Research Council committed up to 300,000 Canadian dollars through its Applied Quantum Computing Challenge program to advance D-Wave's annealing software for commercial deployment.

That cluster of partnerships spanning telecommunications, financial services, and government research programs undercuts the notion that D-Wave is merely a story stock without operational substance.

The Numbers Remain a Reality Check

The second-quarter results, however, keep expectations grounded. Revenue came in at roughly $3.1 million, essentially flat against forecasts, while the net loss narrowed more than some had feared at about $0.10 per share. For a company positioning itself at the forefront of a transformative technology, that revenue figure remains sobering — and it helps explain why the market hasn't rewarded the recent run of positive headlines.

Some observers point to first-half booking momentum as a more meaningful leading indicator than the modest revenue numbers themselves. If order intake is accelerating, the argument goes, the revenue line should eventually follow.

A Governance Reset, Not a Crisis

The leadership transition deserves context. D-Wave had already strengthened its board on August 13 with the appointment of Kevan P. Krysler as an independent Class I director and audit committee member, with a mandate running through the 2029 annual meeting. Adding an experienced financial manager to the oversight function at the same time the CFO departs suggests a deliberate restructuring rather than a scramble.

The market's reaction tells a more complicated story. The stock closed Friday at €14.69, down 4.4 percent on the day and 16 percent for the week. Against the 52-week high of €40.41 reached on October 15, 2025, the shares have shed nearly two-thirds of their value. That decline reflects a stock that traded heavily on speculation last year and is now recalibrating expectations — not necessarily a verdict on the underlying technology.

One counterweight arrived on August 21, when BMO Capital initiated coverage with an Outperform rating, a vote of confidence that coincided almost exactly with the CFO news. The timing offered some relief to investors worried the personnel change signaled deeper problems.

The tension at D-Wave is the classic early-stage industry dilemma: a company delivering on research and partnerships while its revenue base remains thin and its share price punishes any hint of organizational friction. The Nature publication and the expanding partner roster demonstrate that D-Wave is more than a bet on a distant future. Whether that translates into meaningful revenue in the coming quarters is the question the market will keep asking — and the one the stock price will ultimately answer.